Successes and challenges in translational research: The development of targeted therapy for gastrointestinal stromal tumours

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 3908-3911

  Renouf, Daniel J ^a   Wilson, Lora ^b   Blanke, Charles D ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; IMATINIB; STEM CELL FACTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SOLID TUMOR; SYSTEMIC THERAPY; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 67449152478     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1622     Document Type: Review

References (33)

1. Kindblom LG, Meis-Kindblom J, Bumming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal tumors (GIST): A population-based study of 600 cases [abstract]. Ann Oncol 2002;13 Suppl 5:157.
2. Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: The Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005;117:289-293 PubMed doi:10.1002/ijc.21167.
3. Miettinen M, Virolainen M. Maarit-Sarlomo-Rikala. Gastrointestinal stromal tumors-value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995;19:207-216 PubMed.
4. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of cajal and for intestinal pacemaker activity. Nature 1995;373:347-349 PubMed doi:10.1038/373347a0.
5. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-3351 PubMed.
6. Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B, Heldin CH. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J1991;10:4121-4128 PubMed.
7. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580 PubMed doi:10.1126/science.279.5350.577. (Pubitemid 28067289)
8. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710 PubMed doi:10.1126/science.1079666. (Pubitemid 36159485)
9. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8. PubMed doi:10.1097/00000658- 200001000-200100008 (Pubitemid 30043939)
10. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. implications for surgical management and staging. Ann Surg 1992;215:68-77. PubMed.
11. Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. Salvage surgery for patients with recurrent gastrointestinal sarcoma: Prognostic factors to guide patient selection. Cancer 2000;88:66-74. PubMed doi:10.1002/(SICI)1097- 0142(20000101)88:1〈66::AID-CNCR10〉3.0.CO;2-0. (Pubitemid 30027680)
12. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: Atrial of the European organization for research and treatment of Cancer/Soft tissue and bone sarcoma group. J Clin Oncol 2000;18:2676-2684 PubMed. (Pubitemid 30463549)
13. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2000;36:61-7. PubMed doi :10.1016/S0959-8049(99)00240-243 (Pubitemid 30035345)
14. Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002;20:605-612 PubMed doi:10.1081/CNV-120002485. (Pubitemid 37210030)
15. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-3489 PubMed. (Pubitemid 32730085)
16. Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003;98:2693-2699 PubMed doi:10.1002/cncr.11875. (Pubitemid 37509535)
17. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-104 PubMed. (Pubitemid 26011463)
18. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nat Med 1996;2:561-566 PubMed doi:10.1038/nm0596-561. (Pubitemid 26151518)
19. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652 PubMed doi:10.1056/NEJMoa011573. (Pubitemid 34815868)
20. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20:325-334 PubMed doi:10.1200/JCO.20.1.325. (Pubitemid 34032628)
21. McLean SR, Gana-Weisz M, Hartzoulakis B, et al. Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther 2005;4:2008-15. PubMed doi:10.1158/1535-7163.MCT-05- 0070. (Pubitemid 43056984)
22. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-932 PubMed. (Pubitemid 30618049)
23. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications. Oncogene 2001;20:5054-5058 PubMed doi:10.1038/sj.onc.1204704. (Pubitemid 32769795)
24. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056 PubMed doi:10.1056/NEJM200104053441404. (Pubitemid 32267975)
25. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571)i n metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001;358:1421-3. PubMed doi:10.1016/S0140-6736(01)06535-6537 (Pubitemid 33055745)
26. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480 PubMed doi:10.1056/NEJMoa020461. (Pubitemid 34879334)
27. Wilson L. Fairness inlimited-access clinical trials and increased patient participation demand. Poster #1059 presented at 18th UICC International Cancer Congress, Oslo Norway 2008.
28. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-625 PubMed doi:10.1200/JCO.2007.13. 4403. (Pubitemid 351264357)
29. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349 PubMed doi :10.1200/JCO.2003.04.190. (Pubitemid 46621810)
30. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-632 PubMed doi:10.1200/JCO.2007.13.4452. (Pubitemid 351264358)
31. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127-34. PubMed doi :10.1016/S0140-6736(04)17098-17100 (Pubitemid 39296599)
32. Van Glabbeke M, Owzar K, Rankin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analysis based on 1,640 patients. J Clin Oncol 2007;25 Suppl 18:10004.
33. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-38. PubMed doi:10.1016/S0140-6736(06)69446-69454 (Pubitemid 44528723)